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Abstract
Peptidoglycan is an essential and specific component of the bacterial cell wall and therefore is an ideal recognition
signature for the immune system. Peptidoglycan recognition proteins (PGRPs) are conserved from insects to mammals and
able to bind PGN (non-catalytic PGRPs) and, in some cases, to efficiently degrade it (catalytic PGRPs). In Drosophila, several
non-catalytic PGRPs function as selective peptidoglycan receptors upstream of the Toll and Imd pathways, the two major
signalling cascades regulating the systemic production of antimicrobial peptides. Recognition PGRPs specifically activate
the Toll pathway in response to Lys-type peptidoglycan found in most Gram-positive bacteria and the Imd pathway in
response to DAP-type peptidoglycan encountered in Gram-positive bacilli-type bacteria and in Gram-negative bacteria.
Catalytic PGRPs on the other hand can potentially reduce the level of immune activation by scavenging peptidoglycan. In
accordance with this, PGRP-LB and PGRP-SC1A/B/2 have been shown to act as negative regulators of the Imd pathway. In
this study, we report a biochemical and genetic analysis of PGRP-SB1, a catalytic PGRP. Our data show that PGRP-SB1 is
abundantly secreted into the hemolymph following Imd pathway activation in the fat body, and exhibits an enzymatic
activity towards DAP-type polymeric peptidoglycan. We have generated a PGRP-SB1/2 null mutant by homologous
recombination, but its thorough phenotypic analysis did not reveal any immune function, suggesting a subtle role or
redundancy of PGRP-SB1/2 with other molecules. Possible immune functions of PGRP-SB1 are discussed.
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Introduction
In the last decades, peptidoglycan (PGN), an essential compo-
nent of virtually all bacteria, has appeared as a key player in host-
microorganism interactions [1]. This glycopeptidic polymer is a
component of the cell wall of both Gram-negative and Gram-
positive bacteria. It consists of long glycan chains of alternating N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc)
residues, which are cross-linked together via short peptide bridges.
Because PGN is essential to bacteria but absent from eukaryotic
cells, it makes an ideal indicator for metazoan immune systems of
the presence of bacteria within the organism. In addition, the PGN
composition and structure can be markedly different between
bacterial species, allowing the immune system to further
distinguish between different types of intruders. For example, the
PGN of Gram-negative and Gram-positive bacilli-type bacteria
differs from the PGN of most Gram-positive bacteria by the
replacement of lysine (Lys) with meso-diaminopimelic acid (DAP) at
the third position in the peptide chain [2].
On the host side, some protein families have evolved the capacity
to interact with PGN, e.g. lysozymes, Nods (for Nucleotide-binding
Oligomerisation Domain), and peptidoglycan recognition proteins
(PGRPs, or PGLYRPs in the mammalian nomenclature). PGRPs
form a conserved family of proteins sharing a 160 amino acid
domain (the PGRP domain) with similarities to bacteriophage T7
lysozyme, a zinc-dependent N-acetylmuramoyl-L-alanine amidase
[3,4]. First identified in Bombyx mori [5], PGRPs have since been
intensively studied in several insects and vertebrates, including
mammals [4,6,7]. These numerous studies have highlighted the
diversity and importance of PGRP functions in immunity.
PGRPs have been classified in two groups according to their
enzymatic activity. Indeed, some PGRPs have lost their ancestral
amidase activity (non-catalytic PGRPs), while others can still
efficiently cleave PGN (catalytic PGRPs). Non-catalytic PGRPs
have been implicated in functions as diverse as immune receptors,
regulators and effectors [4]. Catalytic PGRPs have been shown to
down-regulate the immune response in insects, act as pro-
inflammatory cytokines in mice, and have bactericidal activity in
zebrafish [8,9,10,11,12]. Recently, it has been reported that
mammalian PGRPs can prevent aberrant inflammatory responses
by modulating the composition of the intestinal bacterial flora, a
function in accordance with the strong expression of PGRPs along
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pate in the establishment of symbiotic interactions in both squid
and insects by preventing the activation of an immune response by
their bacterial symbiont [13,14,15,16].
The Drosophila genome encodes 13 PGRPs and many of them
function both as activators and regulators of the Toll and Imd
pathways [4,17,18]. These two major signalling cascades regulate
the expression of antimicrobial peptides and other immune genes
by the fat body after a systemic infection [19]. Activation of both
pathways by bacteria relies on the sensing of specific forms of PGN
by non-catalytic PGRPs [20]. PGRP-SA and PGRP-SD are
secreted proteins circulating in the hemolymph that activate the
Toll pathway in response to the Lys-type PGN of Gram-positive
bacteria [21,22]. PGRP-LC acts as a transmembrane receptor of
Gram-negative and bacilli DAP-type PGN upstream of the Imd
pathway, with the help of PGRP-LE [23,24,25,26,27]. The Imd
pathway can be activated by both polymeric and monomeric
DAP-type PGN, and the minimal PGN motif for its efficient
induction is tracheal cytotoxin (TCT, or GlcNAc-MurNAc(anhy-
dro)-L-Ala-c-D-Glu-meso-DAP-D-Ala; [28,29]). TCT provides an
ideal indication of Gram-negative bacterial activity since this
monomer, which is located at the terminus of PGN strands, is
released during cell growth and division.
While several Drosophila non-catalytic PGRPs function as
pattern recognition receptors for PGN, the catalytic PGRPs have
demonstrated (PGRP-SC1A/B, LB, SB1) or predicted (PGRP-
SB2, SC2) amidase activity that removes peptides from PGN
glycan chains, thereby reducing or eliminating its immunological
activity [8,30,31,32]. In accordance with this enzymatic activity,
PGRP-SC1A/B/2 and PGRP-LB have been shown to modulate
Imd pathway activation in vivo by scavenging PGN, and also TCT
in the case of PGRP-LB [8,9]. PGRP-SC1A has also been
implicated in the phagocytosis of Staphylococcus aureus [33]. Among
catalytic Drosophila PGRPs, only the function of PGRP-SB1 and
PGRP-SB2 (which is only expressed at pupal stage; [34] - see
Fig. 1A) had not yet been studied in vivo.
In this study, we provide a biochemical and genetic analysis of
PGRP-SB1. Our data show that PGRP-SB1 is abundantly
secreted into the hemolymph following Imd pathway activation
in the fat body. Biochemical studies demonstrate that PGRP-SB1
has enzymatic activity towards DAP-type PGN but does not cleave
TCT. Importantly, we generated a PGRP-SB1/PGRP-SB2 double
mutant by homologous recombination. We show that PGRP-SB1/
2 mutants are viable and do not display a striking phenotype in
any of the classical immune parameters tested: resistance to
infections, local and systemic activation of Toll and Imd pathways
after septic or oral infections, and bacterial persistence in the fly.
Results
PGRP-SB1 is strongly induced by the Imd pathway upon
infection with bacteria containing DAP-type PGN
To characterize the function of PGRP-SB1, we first analyzed its
expression pattern. A Real Time quantitative Polymerase Chain
Reaction (RT-qPCR) analysis revealed a basal level of PGRP-SB1
expression throughout Drosophila development; however, its
expression level was higher at pupal stage, consistent with a
previous Northern blot analysis (Fig. 1A; [34]). Previous micro-
array analysis performed in adult males indicated that PGRP-SB1
is induced 35-fold following septic injury with a mixture of
Micrococcus luteus and Escherichia coli [35]. The comparison of the
different expression profiles revealed that PGRP-SB1 was by far the
strongest induced PGRP after bacterial infection (Fig. 1B). To
investigate whether PGRP-SB1 expression was equally induced by
different bacterial challenges, we monitored PGRP-SB1 expression
after injection of the Gram-negative bacteria Erwinia carotovora,
Gram-positive Listeria monocytogenes or Gram-positive M. luteus.
PGRP-SB1 expression was strongly induced 4 h after infection with
E. carotovora or L. monocytogenes, both of which contain DAP-type
PGN, and remained sustained during the course of infection
(Fig. 1C). In contrast, flies infected with M. luteus, which possesses
Lys-type PGN, exhibited only a slight and brief induction of
PGRP-SB1. In agreement with the microarray analysis [35], we
confirmed that the induction of PGRP-SB1 expression after
E. carotovora or L. monocytogenes injection did not occur in Relish
mutant flies lacking a functional Imd pathway (Fig. 1C).
We next analyzed the expression profile of PGRP-SB1 protein
using a mouse serum raised against PGRP-LB [8] that cross-reacts
with PGRP-SB1 (data not shown). Western blots indicated that
PGRP-SB1 expression was weak in unchallenged adult males,
while the expression level increased 6 h after septic injury with
E. carotovora and reached a maximum at 22 h after infection
(Fig. 1D). PGRP-SB1 was detected as a single band of 18 kDa as
predicted by the genome annotation. In agreement with the
mRNA analysis, PGRP-SB1 was not induced after injection of
E. carotovora in Relish mutant flies (Fig. 1E). PGRP-SB1 was
abundant in protein extracts from both the hemolymph and the fat
body (Fig. 1F). This indicates that PGRP-SB1 is produced in the
fat body upon systemic infection and secreted into the hemo-
lymph, in agreement with the presence of a signal peptide in the
protein.
Altogether, these results indicate that stimulation of the Imd
pathway by bacteria containing DAP-type PGN leads to rapid
PGRP-SB1 synthesis and secretion into the hemolymph.
PGRP-SB1 cleaves DAP-type PGN and specific PGN
fragments, but does not degrade TCT
PGRP-SB1 has been shown to have an amidase activity towards
DAP-type PGN [32]. PGRP-SB1-mediated PGN cleavage was
much weaker towards Lactobacillus casei Lys-type PGN and no
activity was detected towards S. aureus and M. luteus Lys-type PGN
[32]. We extended this analysis by identifying the minimum PGN
motif recognized by PGRP-SB1. In agreement with Mellroth and
Steiner, incubating purified DAP-type PGN derived from E. coli
and L. monocytogenes (see structure in Fig. 2A) with PGRP-SB1 at
37uC resulted in the release of soluble tri-, tetra-, tri-tetra- and
tetra-tetra-peptides, indicative of an N-acetyl muramoyl-L-alanine
amidase activity. Such an activity was not detected against Lys-
type PGN derived from Enterococcus faecalis or Streptococcus pneumoniae
(Fig. 2B, 2C).
TCT (GlcNAc-MurNAc(anhydro)-L-Ala-c-D-Glu-meso-DAP-
D-Ala) has been previously identified as the minimum PGN motif
capable of efficiently inducing the Imd pathway [28,29]. No
amidase activity was observed following incubation at 37uC for
16 h of 2 mg of PGRP-SB1 with 20 nmol of TCT (Fig. 2C)
contrary to what has been shown with PGRP-LB [8]. However,
incubating PGRP-SB1 in the same conditions with TCT dimer
resulted in the cleavage at only one of the two putative amidase
sites, generating disaccharide-octapeptide and free dissacharide
(Fig. 2C). The same experiment with PGRP-LB resulted in the
production of octapeptide and disaccharide [8]. We next analyzed
the effect of PGRP-SB1 on monomer and dimer (with no anhydro
bond) that were purified from mutanolysin treated E. coli DAP-
type PGN. Both the monomer (GlcNAc-MurNAc tetrapeptide
unit) and dimer of muropeptide were hydrolyzed by PGRP-SB1
but PGRP-SB1 was much more active on the dimer (243U
compared to 4U for the monomer). Kinetic studies of the
hydrolysis of GlcNAc-MurNAc tetrapeptide dimer showed a two
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and disaccharide and the slower one leading to octapeptide and
disaccharide (Fig. 2C). This prompted us to test whether such a
preference of PGRP-SB1 for dimeric structures was similarly
observed when polymeric PGN was used as substrate. E. coli PGN
was treated by PGRP-SB1 for different times and the resulting
modifications of the polymer structure were analyzed by a classical
procedure based on HPLC analysis of the pattern of muropeptides
released after degradation of PGN material by SltY. It was
observed that PGRP-SB1 indeed also hydrolyzed dimeric
structures present in PGN much faster (at least 10-fold) than
monomeric ones (Fig. 2C).
Collectively, our results demonstrate that PGRP-SB1 degrades
DAP-type PGN into non-immunostimulatory fragments, but does
not degrade TCT, a key activator of the Imd pathway. We also
observed that the efficacy of PGRP-SB1 is dependent on two
factors, the size of the PGN fragments (monomer, dimer or
polymer) and the MurNAc configuration (anhydro or not).
Generation of a PGRP-SB1/PGRP-SB2 mutant by
homologous recombination
In order to address the function of PGRP-SB1 in vivo, we aimed
to generate a null mutant by homologous recombination. The
PGRP-SB1 locus (720 bp) is located on the 3L chromosome at less
than 150 bp from PGRP-SB2 (615 bp; Fig. 3A). The two
corresponding proteins, of 190 and 182 amino acids respectively,
share 68% similarity (51% identity), but the genes differ in their
expression, as PGRP-SB2 is mainly expressed at the pupal stage
Figure 1. Expression profile of PGRP-SB1. (A) RT-qPCR measurements reveal a low basal expression of PGRP-SB1 at all stages of the Drosophila life
cycle, with a slight enhancement in pupae, while PGRP-SB2 is solely expressed at pupal stage. (B) The expression profile of PGRP-SB1 shows rapid
induction after septic injury with a mixture of E. coli and M. luteus. This induction is much stronger than that observed for other PGRPs. The microarray
data for this figure were extracted from [42]. (C) RT-qPCR analyses indicate that PGRP-SB1 expression is induced upon immune challenge with Gram-
negative bacteria E. carotovora or Gram-positive bacteria L. monocytogenes, both of which contain DAP-type PGN. PGRP-SB1 is not induced upon L.
monocytogenes infection in Relish flies deficient in Imd pathway activation. Septic injury with the Lys-type PGN containing Gram-positive bacteria M.
luteus only weakly induced PGRP-SB1 expression. Or: Oregon (wild-type); Rel
E20: Relish mutant flies. (D) The expression profile of PGRP-SB1 during the
course of an infection is revealed by Western blot analysis. Proteins were extracted from male flies collected at different time points after infection.
Wild-type (WT): Oregon. (E) PGRP-SB1 expression is induced upon immune challenge in wild-type flies but not in Relish flies. Wild-type (WT): Oregon;
Rel
E20: Relish mutant flies. (F) PGRP-SB1 expression is strongly induced in the fat body and the protein is secreted into the hemolymph. Western blot
analyses were performed with proteins extracted from fat body or hemolymph derived from female flies collected at 10 h or 22 h post-infection,
respectively. Hemolymph samples of 50 female flies were used to extract proteins, of which 15 mg were loaded (see Material and Methods). The
absence of a signal with a-tubulin antibody indicates that the hemolymph preparations were not contaminated by cells.
doi:10.1371/journal.pone.0017231.g001
Drosophila Immunity: Analysis of PGRP-SB1
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17231Figure 2. Amidase activity and substrate specificity of recombinant PGRP-SB1. (A) Structure of E. coli PGN (DAP-type). The glycan chains
are formed of alternating GlcNAc (G) and MurNAc (M) residues. Those of E. coli PGN end with a 1,6-anhydro-MurNAc residue (*). The tetrapeptide
motif corresponds to the TCT. Arrows indicate the cleavage sites of N-acetylmuramoyl-L-alanine amidases. The main peptides released following
treatment of cross-linked PGN with PGRP-SB1 are the tetrapeptide L-Ala-c-D-Glu-meso-DAP-D-Ala and its dimer, the octapeptide. (B) Specificity of
PGRP-SB1 on Lys-type and DAP-type PGN was determined by measuring its amidase activity on PGN derived from four bacterial species: E. coli,
L. monocytogenes (DAP-type PGN) and E. faecalis and S. pneumoniae (Lys-type PGN). The amidase activity was followed by analyzing by HPLC the
release of tri- and tetrapeptides and of the corresponding dimers in solution, incubating for 26 h 100 mg of PGN with 2 mg of PGRP-SB1. (C) The PGRP-
SB1 activity was determined on E. coli polymeric PGN and various purified PGN fragments. These fragments were obtained after treatment of E. coli
PGN either with mutanolysin or SltY, generating monomers and dimers of muropeptides (GlcNAc-MurNAc-tetrapeptide units) or anhydro-
muropeptides (GlcNAc-MurNAc(anhydro)-tetrapeptide units, i.e. TCT), respectively. Substrates and products were separated by HPLC, characterized
and quantified. The results are summarized in the scheme and the PGRP-SB1 activity is given in units, 1 unit representing 1 nmol of substrate
hydrolyzed per min and per mg of PGRP-SB1.
doi:10.1371/journal.pone.0017231.g002
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to replace approximately 1.5 kb, corresponding to the ORFs of the
two genes, with a copy of the white gene (Fig. 3A). We obtained
several independent fly lines and two of them, PGRP-SB
D5 and
PGRP-SB
D9, were selected for further analysis. We used RT-qPCR
and Western blot to confirm the absence of PGRP-SB2 transcript
and PGRP-SB1 protein respectively in homozygous PGRP-SB
D5
and PGRP-SB
D9 mutants (Fig. 3B and data not shown). We checked
that the PGRP-SB1/2 deletion did not affect the expression of the
flanking genes CG13026 and Dbp73D (Fig. 3A and data not shown).
As both alleles produced identical results, we only report here data
obtained with PGRP-SB
D5. These mutants were perfectly viable and
fertile, exhibited no visible developmental defects and did not differ
from wild-type flies in longevity (Fig. 3C).
Analysis of the immune phenotype of PGRP-SB
D5
mutants
PGRP-SB
D5 mutants exhibit a wild-type resistance to
systemic microbial infections. To determine the function of
PGRP-SB1 in the Drosophila immune response, we assayed the
susceptibility of PGRP-SB
D5 mutants to injection of different classes
of bacteria. PGRP-SB
D5 mutants were as resistant as wild-type flies
to infections by DAP-type Gram-negative bacteria E. carotovora,
DAP-type Gram-positive bacteria L. innocua and Lys-type Gram-
positive bacteria E. faecalis (Fig. 4).
Induction of the systemic immune response after
injection of bacteria or PGN is not affected in PGRP-SB
D5
mutants. We next tested the ability of PGRP-SB
D5 mutants to
mount an efficient but regulated immune response after injection
of various bacteria. Other members of the PGRP family have been
implicated in both activation of the Toll and Imd pathways
(PGRP-SA, PGRP-LC, PGRP-LE and PGRP-SD) and down-
regulation of the Imd pathway (PGRP-LF, PGRP-LB and PGRP-
SC1A/B/2) [4]. We monitored Toll and Imd pathway activation
after different types of immune challenge by measuring the
expression of two of their target genes, Drosomycin (Drs) and
Diptericin (Dpt) respectively. PGRP-SB
D5 mutants expressed Drs and
Dpt at a wild-type level after injection of E. carotovora (Fig. 5A),
M. luteus (Fig. 5B), L. innocua (Fig. 5C and 5D), or E. coli PGN
(Fig. 5E). However, Dpt expression was slightly higher in PGRP-
SB
D5 mutants 24 h after infection with L. innocua and 6 h after
injection of E. coli PGN (Fig. 5C and 5E). The mild over-activation
of the Imd pathway at one time point after these two challenges
could indicate a moderate action of PGRP-SB1 as a negative
regulator, likely to be masked in most of the cases by the action of
more efficient regulators such as PGRP-LB.
Neither local nor systemic activation of the Imd pathway
after E. carotovora oral infection is affected by the loss of
PGRP-SB1/2. PGRP-SB1 is strongly induced in the fly gut after
oral infection with Gram-negative bacteria ([36] and data not
shown), suggesting a role in the intestinal immune response. We
evaluated such a function by measuring the level of induction of
the Imd pathway both locally and systemically after E. carotovora
oral infection. In wild-type adult flies, E. carotovora ingestion
induces a local immune response but barely any systemic immune
response in the fat body. In contrast to PGRP-LB RNAi flies [8],
PGRP-SB
D5 mutants did not present an increased local immune
response or a strong activation of the systemic response as
compared to wild-type flies (Fig. 5F and 5G). We conclude that
PGRP-SB1/2 do not play a major role in the regulation of
antibacterial peptide genes after oral infection of adult flies.
E. carotovora and L. innocua persistence is similar in
PGRP-SB
D5 mutants and wild-type flies. Our data indicate
that, in contrast to all PGRPs studied so far, the lack of PGRP-SB1/
Figure 3. Generation of a null PGRP-SB1/2 mutation by
homologous recombination. (A) Schematic representation of the
PGRP-SB1/2 deletion. The gene map was adapted from FlyBase (http://
flybase.org/) and includes PGRP-SB1, PGRP-SB2 and the neighboring
genes. The deleted segment replaced by the white gene (grey box) and
the flanking sequences used for recombination (dotted lines) are
indicated. (B) PGRP-SB1 is not expressed in PGRP-SB
D5 and PGRP-SB
D9
mutant flies. The PGRP-SB1 protein cross-reacts with a serum raised
against PGRP-LB and appeared as a band of about 18 kDa on this
Western blot (arrow head). The band was detected in wild-type female
extracts (Or: Oregon) 6 h after injection of E. Carotovora. The protein
was also detected in daughterless-Gal4/UAS-PGRP-SB1 (da.SB1) flies
over-expressing PGRP-SB1 in unchallenged condition. In contrast, the
protein was not detected in uninfected wild-type flies or in PGRP-SB
D5
(SB
D5) and PGRP-SB
D9 (SB
D9) mutants 6 h after injection of E. Carotovora.
SI: septic injury; UC: Unchallenged. (C) Lifespan is not affected in PGRP-
SB
D5 mutant flies. The survival rates (%) of WT and PGRP-SB
D5 mutant
flies at 29uC were measured over 36 days and did not reveal any
differences in longevity. Each line represents an independent experi-
ment for that genotype and gives the mean survival of 2-3 cohorts of 20
flies within that experiment.
doi:10.1371/journal.pone.0017231.g003
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PGRP-SB1 is the most highly inducible PGRP, with an induction
level similar to that observed for antimicrobial peptide genes. A
previous study has indicated that PGRP-SB1 displays some
antibacterial activity against B. megaterium in vitro [32]. This
suggests that PGRP-SB1 could be an effector molecule,
participating in microbe elimination. To test this hypothesis
we monitored the persistence of E. carotovora, L. innocua and
B. megaterium 24 h and 48 h after their injection into wild-type or
PGRP-SB
D5 mutant flies. Whole fly extracts were plated on LB or
BHI-agar medium to assess the number of recovered bacterial
colonies at different time points after infection. Our data indicated
that E. carotovora (Fig. 6A) and L. innocua (Fig. 6B) did not persist
better in PGRP-SB
D5 mutants than in wild-type flies, although
surprisingly, the median persistence of E. carotovora at 48 h was
somewhat lower in PGRP-SB
D5 mutants than in wild-type flies.
B. megaterium appeared unable to survive injection into flies,
preventing an assessment of the effect of PGRP-SB1/2 mutations
on its persistence (data not shown).
PGRP-SB1 over-expression is not sufficient to protect
from L.innocua infection
PGRP-SB1 being an efficient enzyme for DAP-type PGN
degradation, we last aimed to test the hypothesis that PGRP-SB1
had a protective function against Gram-positive DAP-type
containing bacteria, such as Listeria. Indeed, in these bacteria the
PGN participates to the outer cell wall layer and could thus be
directly accessible for PGRP-SB1, while in Gram-negative
bacteria the PGN is ‘‘hidden’’ by the outer lipopolysaccharide
layer. Therefore, we injected L. innocua in flies over-expressing
PGRP-SB1 and assessed their viability as well as the bacteria
persistence in these flies as compared to wild-type flies. Our data
show that PGRP-SB1 over-expression is not sufficient to protect
from the morbidity associated with this infection, or to decrease
the number of persisting bacteria in the fly at 24 hours (Fig. 7).
In conclusion, our thorough analysis of various immune
parameters (resistance to infections, activation of local and
systemic immune responses after infection by injection or feeding,
bacterial persistence in the fly) did not reveal a striking immune
function for PGRP-SB1 and SB2, despite the use of a null mutant.
Discussion
The PGRP family has been thoroughly studied in the last
decade, both in Drosophila and in vertebrates. We present here an
extensive analysis of the expression, enzymatic activity and
immune phenotype of PGRP-SB1, one of the last Drosophila PGRPs
(alongside PGRP-LA and PGRP-LD) whose functions remain
uncharacterized in vivo. This is also the first analysis of a complete
genetic knockout of two catalytic PGRPs in Drosophila,a s
previously published in vivo studies of PGRP-LB and PGRP-SC1/2
have relied either on RNA interference or on uncharacterized
mutations [8,9,33].
In this study, we have demonstrated that PGRP-SB1 expression
is highly induced after infection, far more than for any other
PGRP and to an extent similar to that of effectors such as
antimicrobial peptide genes. PGRP-SB1 is abundantly produced
in the fat body, and then released into the hemolymph. It has an
amidase activity against DAP-type PGN. Taken together with the
in vitro bactericidal activity of PGRP-SB1 against a DAP-type
containing bacteria [32] these data suggest an effector function.
Although our mutant analysis did not reveal any increase in
susceptibility to infection or in bacterial persistence in PGRP-SB
D5
flies, it is expected that the removal of one out of many effectors
Figure 4. PGRP-SB1 is not required for resistance to bacterial
infections. The survival rates (%) of PGRP-SB
D5 mutant flies injected
with the DAP-type PGN containing Gram-negative bacteria E. caroto-
vora (A), the Lys-type PGN containing Gram-positive bacteria E. faecalis
(B) or the DAP-type PGN containing Gram-positive bacteria L. innocua
(C) were compared to wild-type flies Oregon (Or) and Canton-S (Cs) and
flies defective in either the Toll pathway (spa ¨tzle mutants; spz
rm7) or the
Imd pathway (Relish mutants; Rel
E20). PGRP-SB
D5 mutation did not
modify the fly resistance to these bacterial infections. Optical densities
of the bacterial strains used in these experiments are indicated in the
Material and Methods section. One representative experiment out of
three (E. carotovora, L. innocua) or two (E. faecalis) repeats is shown.
doi:10.1371/journal.pone.0017231.g004
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or synergy. This could also explain the non-protective effect of
PGRP-SB1 over-expression after L. innocua infection. For example,
PGRP-SB1 could need the activity of another protein to have
sufficient access to its PGN substrate. On the other hand, PGN
cleavage by PGRP-SB1 could increase with its over-expression but
not be sufficient to eliminate the bacteria in absence of expression
of a co-factor. Therefore a function of PGRP-SB1 as an effector
remains a possibility.
There are several other possible explanations for the lack of an
immune phenotype in the PGRP-SB
D5 mutants. Firstly, PGRP-
SB1/2 could have a function at a specific stage or tissue that would
not be revealed by our analysis, based as it was on whole organism
infections/responses and restricted to the adult stage. Indeed,
Figure 5. Antimicrobial peptide gene expressions in PGRP-SB1/2 mutant flies after different immune challenges. (A) Injection of
E. carotovora in PGRP-SB
D5 mutants induced Diptericin (Dpt) expression, a read-out of the Imd pathway activation, at a similar level to wild-type flies.
(B) PGRP-SB
D5 mutants injected with M. luteus expressed Drosomycin (Drs), a read-out of the Toll pathway activation, at a wild-type level. (C) Injection
of L. innocua in PGRP-SB
D5 mutants induced Dpt expression at a similar level to wild-type flies, except at 24 h after infection when Dpt expression was
slightly higher in PGRP-SB
D5 mutants than in wild-type flies. (D) Injection of L. innocua in PGRP-SB
D5 mutants induced Drs expression at a similar level
to wild-type flies. (E) Injection of E. coli PGN in PGRP-SB
D5 mutants induced Dpt expression at a similar level to wild-type flies, except at 6 h after
injection when Dpt expression was slightly higher in PGRP-SB
D5 mutants than in wild-type flies. (F and G) PGRP-SB
D5 mutants orally infected (OI) with
E. carotovora expressed Dpt at a wild-type level both locally in the gut (F) and systemically in the fat body (G). UC: unchallenged. Dpt or Drs gene
expression was monitored by RT-qPCR performed on total RNA extracts from wild-type (WT; Oregon) and PGRP-SB
D5 mutant females. mRNA levels
were normalized to RpL32 mRNA. (A–E) The ratios indicated are either relative to wild-type ratio at 24 h (A and B) or 6 h (C–E) after infection, or
absolute (F–G). The results are presented as the mean and standard error of three independent experiments.
doi:10.1371/journal.pone.0017231.g005
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could have a role during metamorphosis, although we did not
notice any developmental defect of PGRP-SB
D5 mutants. Secondly,
PGRP-SB1 could have a more subtle immune function against a
specific natural pathogen of the fly, untested here, or in other
immune reactions, e.g. phagocytosis (as published for PGRP-
SC1A [33]). Thirdly, as the deletion we have generated affects
both PGRP-SB1 and SB2, we cannot exclude the possibility that
the phenotype of one mutation is suppressed by the phenotype of
the other, as could be the case if the functions of these two genes
were antagonistic. However, we consider this hypothesis unlikely
because of the restriction of PGRP-SB2 expression to the pupal
stage. Finally, PGRP-SB1 could have redundant regulatory
functions with other catalytic PGRPs, as suggested by the mild
and time restricted over-activation of the Imd pathway we noticed
after injection of L. innocua bacteria and E. coli PGN. This
hypothesis could be addressed by generating fly lines carrying
mutations of multiple PGRPs.
Our data demonstrate that while it efficiently degrades
polymeric and DAP-type PGN fragments, PGRP-SB1, unlike
PGRP-LB, does not cleave TCT ([8] and this study). This suggests
that the presence of large quantities of PGRP-SB1 in the
hemolymph, in spite of degrading PGN polymers, would not fully
suppress Imd pathway activation by Gram-negative bacteria, due
Figure 6. Persistence of E. carotovora and L. innocua bacteria is
not affected by the PGRP-SB
D5 mutation. Persistence of
E. carotovora (A) and L. innocua (B) bacteria in PGRP-SB
D5 mutant flies
and wild-type flies was assayed at 0 h, 24 h and 48 h after injection, by
spotting serial dilutions of fly extracts on LB- or BHI-agar Petri dishes (20
flies per data point). The values, which correspond to the results of
three independent experiments, each made in duplicate, indicate the
number of CFU (colony-forming unit) per fly. The median is indicated by
a horizontal line. Wild-type flies: Oregon (Or); PGRP-SB
D5 mutant flies:
SB
D5.
doi:10.1371/journal.pone.0017231.g006
Figure 7. Over-expression of PGRP-SB1 is not sufficient to
protect from L. innocua infection. (A) The survival rate (%) of flies
over-expressing PGRP-SB1 (daughterless(da)-Gal4/UAS-PGRP-SB1;
da.SB1) injected with the DAP-type PGN containing Gram-positive
bacteria L. innocua was compared to the survival rate of wild-type flies
Oregon (Or) and flies defective in the Imd pathway (Relish mutants;
Rel
E20). PGRP-SB1 over-expression did not modify the fly resistance to
this infection. L.i.: L. innocua; UC: unchallenged. One representative
experiment out of three is shown. (B) Persistence of L. innocua bacteria
in flies over-expressing PGRP-SB1 (da.SB1) and wild-type flies (Oregon;
Or) was assayed at 0 h and 24 h after injection, by spotting serial
dilutions of fly extracts on LB- or BHI-agar Petri dishes (20 flies per data
point). The values, which correspond to the results of two independent
experiments, each made in duplicate, indicate the number of CFU
(colony-forming unit) per fly. The median is indicated by a horizontal
line.
doi:10.1371/journal.pone.0017231.g007
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growth and division. By contrast, PGRP-LB degrades all
immunogenic forms of DAP-type PGN and thus can completely
suppress the immune response to PGN [8]. This substrate
specificity among catalytic PGRPs might reflect a requirement
for an effector function which does not eliminate the immune
response. The specificity of PGRP-SB1 enzymatic activity could
contribute to the elimination of bacteria by degrading their cell
wall, while allowing TCT to accumulate and continue to activate
the other branches of the immune response. Similarly, the
cleavage of PGN could allow a distinction to be made between
dead bacteria, whose lysis would release polymeric PGN, and
alive, rapidly dividing bacteria, which are potentially harmful and
would release TCT. The substrate specificity of PGRPs might thus
allow fine-tuning of the immune response. From this point of view,
it would be interesting to determine the substrate specificity and
minimal molecular requirements of PGRP-SC1A, SC1B and SC2.
Recent work on PGRPs has highlighted the complexity of the
interactions between bacterial PGN and host proteins [37]. In
addition, it seems that these interactions have evolved differently
depending on needs and bacterial exposure of the host species.
Thanks to the broad spectrum of their ligand and substrate
specificities, PGRPs function both as symbiosis facilitators and as
immune activators, effectors and regulators [4,13,14,15,16,18].
This diversification reflects the importance of PGN/host protein
interactions for the communication between symbiotic, commen-
sal or pathogenic bacteria and their host. We believe that the
systematic analysis of PGRP expression patterns, enzymatic
activities and in vivo functions is a powerful approach to decipher
the complexity of these interactions.
Materials and Methods
Fly stocks and transgenic and mutant generation
Oregon
R flies were used as wild-type controls. spz
rm7 and Rel
E20
alleles are null mutations in spa ¨tzle and Relish respectively [20,38].
Drosophila stocks were maintained at 25uC using standard fly
medium.
A deletion of the PGRP-SB1 and SB2 locus was obtained by
homologous recombination [39]. 3,715 bp and 4,252 bp sequences of
DNA flanking the 59 and 39 ends, respectively, of the PGRP-SB1/2
locus (Fig. 3A) were cloned in the pW25 vector [39]. The primers used
were F: 59-GCAGCGGCCGC CAGTTGCAATTCCACGCC-39
and R: 59-CGTGGTACCCTTTCGGTCACCGATCTGC-39 for
the 3,715 bp fragment, and F: 59-GCAGGCGCGCCTTTTACGG-
GAAACGAAGCG-39 and R: 59-CGTCGTACGAATCCGGCA-
CATGTGCG-39 for the 4,252 bp fragment. 1,525 bp of PGRP-SB1
and SB2 sequences (3L: from nucleotide 16719625 to 16721150) were
replaced by the white gene.
To generate UAS-PGRP-SB1 transgenic flies, a full-length cDNA
of PGRP-SB1 (using the CG9681_cDNA full length IP02762 from
DGRC) was inserted in the pDONR221 Gateway entry clone
(Invitrogen) and finally subcloned in pTW transgenesis vector. The
transgenic flies were obtained by P-element transgenesis. Over-
expression of PGRP-SB1 was achieved by crossing the resulting
UAS-PGRP-SB1 transgenic flies with flies carrying the ubiquitous
daughterless-Gal4 driver. F1 progeny was transferred to 29uC at late
pupal stage for optimal efficiency of the UAS/Gal4 system.
Bacterial strains and infection experiments
Systemic bacterial infections were performed by pricking adults
in the thorax with a thin needle previously dipped into a
concentrated pellet of a bacterial culture [40]. Infected flies were
subsequently maintained at 29uC. A minimum of 40 flies were
used for survival experiments and survival was scored either twice
a day or daily as appropriate. The bacteria strains used and their
respective optical density (O.D.) at 590 nm were: the DAP-type
PGN containing Gram-negative bacteria Erwinia carotovora [41]
(E. carotovora, O.D. 200), the DAP-type PGN containing Gram-
positive bacteria Listeria monocytogenes (L. monocytogenes, O.D. 80),
Listeria innocua (L. innocua, O.D. 200) or Bacillus megaterium
(B. Megaterium, O.D. 200), and the Lys-type PGN containing
Gram-positive bacteria Micrococcus luteus (M. luteus, O.D. 200) and
Enterococcus faecalis (E. faecalis, O.D. 15). Strains were cultured in
Brain-Heart Infusion Broth (BHI - Listeria) or Luria Broth (LB - all
others) at 29uC( E. carotovora)o r3 7 uC( Listeria, E. faecalis,
B. megaterium, M. luteus). E. coli PGN was used at a monomer
equivalent concentration of 5 mM and injected into the thorax of
adult females at 18.4 nl per fly using a Nanoject apparatus
(Drummond
TM).
For the measurement of in vivo persistence, 9.4 nl of bacterial
culture at O.D. 10 were injected into the thorax of female adults
(3–4 days old) using a Nanoject apparatus (Drummond
TM).
Persistence of the bacteria was evaluated at 24 and 48 h post-
infection by crushing 20 flies in either BHI (L. innocua)o rL B
(E. carotovora, B. megaterium) culture medium. Serial dilutions of
these extracts were spotted in triplicate on appropriate medium
and incubated overnight at 29uC( E. carotovora)o r3 7 uC( L. innocua,
B. megaterium). Colonies were counted from spots containing more
than 10 colonies.
Oral infections were performed by feeding adults with an O.D.
200 pellet of E. carotovora supplemented with sucrose, as described
previously [40].
Western blot analysis
Western blots were performed with a mouse polyclonal
antibody directed against recombinant PGRP-LB (30 kDa) that
also recognizes PGRP-SB1. Indeed, a band of about 18 kDa was
detected in wild-type fly extracts 6 h after E. carotovora injection as
well as in unchallenged flies over-expressing PGRP-SB1 (daughter-
less-Gal4, UAS-PGRP-SB1), but not in extracts from PGRP-SB
D5
mutants (Fig. 3B). A monoclonal anti a-tubulin antibody
(Molecular Probes
TM) was used as a loading control. Samples
corresponding to hemolymph from 50 female flies (extracted as
described in [8]), were lysed in 26Laemmli solution. 15 mg of the
protein extracts were loaded on a 7.5% SDS-polyacrylamide gel.
Following SDS-PAGE, proteins were blotted onto Hybond ECL
nitrocellulose membranes (Amersham LIFE Science). The blots
were developed using the ECL system (Amersham) and X-ray
films.
Quantitative real-time PCR (RT-qPCR)
For Dpt, Drs, PGRP-SB1 and PGRP-SB2 mRNA quantification
from whole animals or guts, RNA was extracted using RNA
TRIzol
TM. For whole animals, 10 flies were used for each sample;
for guts, 20 dissected guts from the crop to just above the
malpighian tubules were used. cDNAs were synthesized using
SuperScript II (Invitrogen) and PCR was performed using dsDNA
dye SYBR Green I (Roche Diagnostics). Primer pairs for Dpt
(sense, 59-GCTGCGCAATCGCTTCTACT-39 and antisense, 59-
TGGTGGAGTGGGCTTCATG-39), Drs (sense, 59-CGTGAGA-
ACCTTTTCCAATATGATG-39 and antisense, 59-TCCCAGG-
ACCACCAGCAT-39), PGRP-SB1 (sense, 59-ATGAACACATC-
AACGGCA-39 and antisense, 59-CCGGAAATCCTAGAAGGC-
39), PGRP-SB2 (sense, 59-GCTCTCGTTCTATGTGGA-39 and
antisense, 59-CCCTGAACTTTCTGCG-39) and RpL32 (sense,
59-GACGCTTCAAGGGACAGTATCTG-39 and antisense, 59-
AAACGCGGTTCTGCATGAG-39) were used. SYBR Green
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mRNA detected was normalized to control RpL32 mRNA values.
We used normalized data to quantify the relative level of a given
mRNA according to cycling threshold analysis (DCt), hence data
are plotted for example as DCt Dpt/DCt RpL32.
Purification of peptidoglycan and peptidoglycan
fragments
Gram-negative and Gram-positive PGN preparations were
described in [20]. E. coli PGN was purified from the BW25113
Dlpp::Cm
R strain that does not express the Braun lipoprotein.
Digestion of this material by pure SltY lytic transglycosylase was
used to produce mg quantities of TCT and dimer of TCT purified
as described previously [29]. Radiolabelled PGN was generated by
incorporation of meso-[
3H]DAP in the FB8 lysA::kan strain grown in
M63 minimal medium supplemented with 0.2% glucose and
100 mg.ml
21 of lysine, threonine and methionine, as previously
described. Muropeptide fragments of PGN were generated by
digestion with mutanolysin as described in [29]. Muropeptides
were not reduced before incubation with PGRP-SB1 and HPLC
separation. In these conditions they are eluted in two peaks
(anomers a and b).
Amino acid and amino sugar compositions were determined
and quantified with a Hitachi L8800 amino acid analyzer
(ScienceTec) after hydrolysis of samples with 6 M HCl for 16 h
at 95uC. The structure and purity of isolated PGN fragments and
synthesized compounds were further confirmed by MALDI-TOF
mass spectrometry.
Expression of recombinant PGRP-SB1 and assay for
N-acetylmuramoyl-L-alanine amidase activity
His-tagged PGRP-SB1 was expressed in S2 cells and purified as
described previously [32].
The amidase activity of PGRP-SB1 was assayed in a reaction
mixture (50-100 ml) containing 50 mM Tris buffer (pH 8), 2 mM
ZnSO4, pure PGN (100-20 mg) or PGN fragment (2-20 nmoles),
and PGRP-SB1 (1-2 mg). After incubation at 37uC for 26 h or
16 h, the reaction was stopped by addition of 2 ml phosphoric or
acetic acid and 500 ml HPLC elution buffer: 50 mM sodium
phosphate, pH 4.5. To analyze the effects of PGRP-SB1 on the
PGN structure in more detail, samples of PGN were first
incubated with PGRP-SB1, as described above, for different
periods of time, from 20 min to 24 h. Then, reactions were
stopped by boiling for 5 min and mixtures were centrifuged.
Supernatants were stored for subsequent HPLC analysis of the
released soluble peptides (tri, tetra, tetra-tetra…). Pellets of
remaining polymeric PGN were treated for 24 h by pure SltY
enzyme and the pattern of muropeptides thus generated (TCT,
TCT dimer…) was analyzed by HPLC [29]. In all cases, mixtures
were injected on a column of Nucleosil 5C18 (4.66150 or 250 mm)
(Alltech France) and products were eluted at a flow rate of
0.6 ml.min
21 using a gradient of methanol or acetonitrile from 0
to 20% in 40 or 100 min. Peaks were detected either by
measurement of the absorbance at 215 nm (and collected for
analysis) or by detection of radioactivity (radioactive flow detector,
model LB506-C1, Berthold).
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